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How has the development of human induced pluripotent stem cells (hiPSCs)modified the trajectory
of stem cell research? Here, coauthorship networks of stem cell research articles and analysis of
cell lines used in stem cell research indicate that hiPSCs are not replacing human embryonic
stem cells, but instead, the two cell types are complementary, interdependent research tools.
Thus, we conclude that a ban on funding for embryonic stem cell research could have unexpected
negative ramifications on the nascent field of hiPSCs.Just 5 years ago, the term pluripotence
referred to a characteristic feature of
only one type of human cell: human em-
bryonic stem cells (hESCs). But when
human induced pluripotent stem cells
(hiPSCs) burst upon the scene in 2007,
this all changed. hiPSCs are derived by
reprogramming somatic cells into an
embryo-like state through the expression
of specific transcription factors. Like
hESCs, hiPSCs are capable of differenti-
ating into any tissue type in the body
(Takahashi et al., 2007; Yu et al., 2007).
Thus, hiPSCs have been hailed as
groundbreaking because they offer a
much clearer path to disease-based
modeling and individualized therapies
compared to older, more genetically
homogeneous hESC lines (Mosher et al.,
2010). Given that generating hiPSCs
involves a relatively straightforward re-
programming technique, will hiPSCs
‘‘democratize’’ the stem cell field by
bringing pluripotent cells within the reach
of many labs that have shied away from
the use of more controversial and
restricted hESCs?
In general, United States policy pro-
hibits research on human embryos and
restricts federal funding to hESC lines
previously approved and listed on a
national registry. This changed dramati-
cally in August 2010 when a federal circuit
judge issued an injunction blocking fund-
ing for new hESC research. By contrast,
hiPSCs are made with somatic cells, not820 Cell 145, June 10, 2011 ª2011 Elsevier Inembryos, and therefore are not as contro-
versial as hESCs and not subject to
federal restrictions. But what is still not
clear is how the emergence of these new
pluripotent technologies, combined with
these policies, impacts the adoption of
new lines, the dissemination of existing
lines, and the extent to which hiPSCs
are supplanting or augmenting estab-
lished hESC research. Complicating
matters, some investigators now suspect
that hiPSCs and hESCs differ signifi-
cantly, issuing calls for research that
uses both types of cells, most especially
comparative studies. New findings have
underscored these distinctions, pro-
voking debate about the possible use of
hiPSCs for disease models and therapies
(Pera, 2011; Lister et al., 2011; Hu et al.,
2010; Zhao et al., 2011).
Are reprogramming technologies
broadening access to pluripotent cell
lines and expanding the reach of stem
cell research? If so, we hypothesize that
we would expect the following: (1) the
uptake of hiPSCs in the published litera-
ture to be significantly faster than that
observed for more restricted hESC lines;
(2) the amount of research that uses
hiPSCs without also relying on hESC lines
to grow, indicating that the new tech-
nology obviates the need for scientists
to choose embryonic cell lines; (3) scien-
tists working with hiPSCs to report less
apprehension about or difficulty with
access to research materials and fundingc.than investigators whose research
depends wholly on more restricted
hESCs; and (4) the use of hiPSCs to
increase in labs with little or no experience
using hESCs.
This Commentary examines these four
assertions by mapping the trajectories of
hESC and hiPSC technologies. We
analyze data collected from 2086 hESC
and hiPSC publications and brief face-
to-face surveys with 118 active re-
searchers (30.9% of 381 poster pre-
senters at the 2010 ISSCR meeting in
San Francisco) to examine how hiPSCs
have been used in the years immediately
following their discovery. These data
allow us to evaluate the impacts that
hiPSCs might exert on the more mature
field of hESC research.
hiPSCs are a young technology, and
the field may yet grow in unexpected
directions as it matures. Nevertheless,
our data offer important insights for
contemporary legal and policy debates
about the legality and scope of federal
funding for hESC research. Our findings
strongly suggest that judicial or legislative
decisions that bear upon support for
human embryonic stem cell research are
likely to strongly impact the character
and direction of human induced pluripo-
tent stem cell research. In particular,
removing or curtailing federal funding for
the former will also have disastrous
consequences for the latter because
research using the two different types of
Figure 1. Publication Analyses
(A) hESC and hiPSC publication trends from 1998 to 2010.
(B) Uptake of hESC and hiPSC in publications immediately following initial discovery.cell lines is deeply, perhaps inextricably,
intertwined.
The Rise of Reprogramming
Technologies
If hiPSCs are increasing access to plurip-
otent cell types, we expect to see rela-
tively quick uptake of the new method.
Indeed, tracking the number of publica-
tions yearly since 1998 that use human
pluripotent stem cells (Figures 1A and
1B) suggests that this is the case. Since
the publication of the first two papers on
hiPSCs in 2007 through 2010, we see
a rapid rise of both hESC and hiPSC publi-
cations.
Several factors may contribute to the
fast emergence of publications on iPSCs,
including their ease of use and access,
their therapeutic potential, the entrance
of new labs and investigators into the
field, and the application of previously
optimized hESC culture conditions. This
increase could also be due to the reaction
of established hESC scientists to 8 years
of funding restrictions under the Bush
administration and the funding uncer-
tainties for hESC lines. On the other
hand, the Obama administration has
made some new lines eligible for funding
since 2009, and thus the rise in hESC
use may result from the adoption of these
new lines, anticipation of increased
federal funding under the new administra-
tion, or access to increased sources of
state support for hESC research across
this time period (Karmali et al., 2010).
Nevertheless, the uptake of induced
pluripotent cell methods is dramaticallyfaster than the rate observed for hESC
lines in the 3 years immediately following
their discovery in 1999 (Figure 1B).
Although labs working with hESCs in the
1990s were claying the scientific ground-
work and publishing their results in
a growing number of journals, we believe
these differences may be due in part to
the profound difference in the policy envi-
ronments surrounding these technolo-
gies. Embryonic stem cell researchers in
the late 1990s and early 2000s faced not
only a restrictive political and regulatory
environment but also public controversy
surrounding the use of frozen embryos
to derive new lines and a complicated
and expensive process for accessing ex-
isting cell lines protected by patent rights.
The chilling effect of George W. Bush-era
policies is also clear from Figure 1A, which
suggests that it took hESC publications
a full 6 years (until 2003) to surpass the
number of hiPSC articles published just
2 years after their discovery. In broad
strokes, it appears that hiPSC technolo-
gies are being adopted much more
rapidly than hESCs were.
hiPSCs and hESCs Together
or Separately?
But are hiPSCs complements or substi-
tutes for hESCs? Using information from
the body of papers and supplemental ma-
terial,wecharacterized the typesof plurip-
otent stem cell lines used in publications
from 2008–2010 (Figure 2). We coded the
papers as using hiPSCs alone, hESCs
alone, or both cell types. We also coded
the cell lines used in 381 research postersCell 1presented at the June 2010 International
Society of Stem Cell Research (ISSCR)
meeting held in San Francisco, CA.
The proportion of papers using hiPSCs
and hESCs together is growing faster than
those using hiPSCs alone. In 2008, only
5.1% (15) of all papers analyzed used
any induced pluripotent cell lines and
only 20% (3) of those combined hESCs
and hiPSCs in the same research manu-
script. By 2010, 28.0% (161 of 574) of all
pluripotent cell papers used hiPSC tech-
nologies, but 62.1% (100 of 161) of those
paired induced and embryonic cell lines.
Thus, although induced pluripotent stem
cells are quickly becoming an important
part of the field, they do not appear to
be replacing work using embryonic cell
lines. Instead the two types of cells are
increasingly used together. Figure 2
suggests that hiPSCs may provide
a limited avenue for new investigators to
enter the field if established hESC
researchers come to dominate in publica-
tions using the new technique. On the
other hand, we could be witnessing
a vetting period for hiPSCs as experi-
enced researchers contrast the true utility
of a possible eclipsing technology.
Access and Utility in Cell Lines
In prior work, we have shown that the
patterns of research materials used by
scientists can be gleaned from analyzing
the research literature, but the underlying
reasons why researchers chose particular
cell lines over others are not always
obvious from publications (Scott et al.,
2009, 2010). To probe this question, we
surveyed 118 researchers who presented
posters about pluripotent stem cells at the
2010 ISSCR meeting. We scored and
categorized the surveys based on two
major themes that characterize the field:
the ‘‘utility of materials’’ category scored
comments about why the lines were
used, and the ‘‘access to specific mate-
rials’’ category scored comments on
how the lines were obtained (for details,
see Supplemental Information and Table
S1).
Access
Investigators using only hESCs mani-
fested the most complicated thinking
about access to research materials.
Perhaps because embryonic lines are
the core of their research programs they
evinced greater concerns about access45, June 10, 2011 ª2011 Elsevier Inc. 821
Figure 2. Proportion of Research by Cell Line Type Usedto federal funding and the
eventual disposition of partic-
ular lines under the Obama
policy. They also expressed
greater reliance on state
funding as an alternative to
federal funding and des-
cribed more diverse routes
to access specific lines.
Many scientists explained
how regulatory uncertainty
and funding dilemmas could
impede their research. For
example, a California re-
searcher who relies on aspecific hESC line said, ‘‘Bottom line is
the ability to work with them. CIRM [Cali-
fornia Institute for Regenerative Medicine]
gives me confidence because I know I’m
funded. I’m glad I’m in California.’’ The
vagaries of federal regulation caused
one New Jersey researcher to derive
a new line for NIH approval when state
funding was dropped for a project using
H9. After a 9month delay, H9 was eventu-
ally approved under new NIH guidelines.
Another scientist remarked that federal
policy has ‘‘a huge impact on the study,
as our investigation had to give up NIH
funding to work on the cell lines.’’
Geography also played a role. One US
investigator moved to Belgium in order
to derive new lines. ‘‘I work on methods
for improved derivation of hESC lines.
We created 15 new lines in the process
of [our] investigation.’’ Researchers
working in other countries remarked that
their ability to derive and use new lines
either was not encumbered by restrictions
(Sweden) or was handicapped in some
fashion (Germany).
Researchers accessed hESC lines in
numerous ways. Some purchased them
from companies whereas others obtained
them from collaborators. Others con-
tinued to use specific lines because they
were repeating previous work or because
they were assigned to an ongoing pro-
ject. Banking, core facilities, and other
repositories also played a role. One re-
searcher remarked, ‘‘I needed a line and
I learned I could get them across the
street at the New York Stem Cell Foun-
dation. They gave a vial to me the same
day.’’
In contrast, the remarks by scientists
using only iPSCs suggested that access
was unproblematic because deriving822 Cell 145, June 10, 2011 ª2011 Elsevier Innew cell lines was easy. Most concerns
involved whether to derive lines specific
to the needs of the lab or to obtain them
from collaborators. When investigators
volunteered information about the source
of somatic cells used for reprogramming,
they generally reported easily accessible
tissue banks as their sources. There
were very fewmentions of fundingworries
and none of policy restrictions. Investiga-
tors were split about evenly between
those who derived their own lines and
those who requested materials from other
labs.
Researchers who used both iPSC and
hESC lines declared less concern with
federal funding and access than those
using only hESCs but more worries
than those who focused only on iPSCs.
There was little concern among these
scientists about the uncertainty intro-
duced by changes in federal funding
rules under the Obama administration
and state alternatives to NIH research
support. We attribute this to the fact
that many of the combinatorial experi-
ments featured federally approved hESC
lines, most notably H1, H7, and H9. In
some cases, laboratories in this category
were experienced hESC users, and thus
studies comparing iPSCs and hESCs
were the logical next step: ‘‘H1, H7, and
H9 were already in the [lab],’’ one
researcher said. ‘‘.so we used the three
lines as controls.’’
Notably, when asked about access,
researchers who used both hESCs and
iPSCs almost unanimously replied by
describing how they obtained their hESC
lines. Although survey respondents re-
ported multiple means to access hESC
lines, they focused on informal routes
and the legacies of past research.c.Utility
In the 38 interviewswith hESC
researchers for whom utility
was an important theme, 25
(65.8%) mentioned the H1,
H7, or H9 lines explicitly.
Discussions about the utility
of particular research mate-
rials thus hinged on deter-
mining which line among a
small set of available possibil-
ities was the most satisfac-
tory. Investigators using only
hESCs evinced different
conceptions of utility. Partic-ular lines were considered valuable
because they were known quantities (in
scientific and regulatory terms) and thus
were valuable as references in experi-
ments that used or derived new lines.
‘‘We wanted to use H1 because they’re
less likely to spontaneously differentiate,’’
a researcher noted.
Overwhelmingly, investigators using
only iPSCs picked the cells because of
the scientific excitement surrounding the
technology, for their ease of derivation,
and for their therapeutic usefulness. This
researcher summed it up: ‘‘[We use
iPSC] because it is an exciting new tech-
nique and it’s fascinating to figure out
potential therapeutic implications. And,
it’s a powerful comparison to what we
know about hESCs.’’ Descriptions were
framed in reference to particular diseases
or markers for specific patient popula-
tions or because the disease-based
tissue banks were readily available.
Somatic cells were sourced in the US,
Africa, Italy, Australia, Finland, and
Germany, and diseases and disorders
included autism, cardiac disease, HIV,
TB, and liver failure, suggesting a broad
genetic diversity of lines.
For researchers using both types of
lines, utility was framed in terms of
comparing iPSCs to the best-known qual-
ities of hESCs. Only one researcher noted
disease as a study aim and then only in
the context of obtaining patient-specific
lines. Because many of these labs had
already studied hESCs, it was only natural
that comparative work would follow. ‘‘It’s
always good to use at least H9 as confir-
mation,’’ noted one researcher. Another
said, ‘‘H9 is the standard. It’s needed for
a positive control.’’ One scientist noted
the conspicuous presence of hESC
Figure 3. Coauthorship Network of Human Pluripotent Research Articles
The network represents coauthorship connections among 5004 researchers publishing articles on hESCs and hiPSCs from 1998 to 2009. 509 (9.23%, n = 5513)
authors are not connected to the primary network component and are not represented. Node size is proportional to articles on hESC or hiPSC articles in 2008–
2009.controls in the literature: ‘‘.we haven’t
seen papers on iPSCs without compar-
ison to ES lines.’’
Coauthorship and Collaboration
In this final section, we analyze networks
of coauthorship to determine whether
senior researchers who use hiPSC tech-
nologies are also deeply embedded in
the established field of hESC research.
Coauthorship of publications is a key rela-
tionship defining scientific disciplines and
fields (Moody, 2004; Newman, 2010), and
it often encompasses sharing of mate-
rials, expertise, goals, and sometimes
students and fellows. We treat the last
authors on publications as senior repre-
sentatives of labs, and we do not account
in our images for the possibility that joint
senior authorship driven by multilab
collaborations may be represented by
shared corresponding authorship.
We present two network figures that
portray the penetration of hiPSC researchinto the hESC field, focusing on the work
performed by more senior scientists
(Figure 3 and Figure 4). First, we assem-
bled the entire coauthorship network for
stem cell articles published between
1998 and 2010 (Figure 3). In this image,
nodes represent authors, and ties repre-
sent coauthorship on one or more papers.
Repeated patterns of coauthorship create
a network structure that includes the
majority (90.8%) of scientists who have
published using hESC and hiPSC lines.
We color-coded nodes to highlight the
activities of last (or senior) authors on
papers published in 2008 and 2009. The
size of the node reflects the number of
papers that an author published in 2008–
2009. Large white nodes represent first
and middle authors from 2008–2009
publications. Small white nodes over-
whelmingly represent authors on pre-
2008 stem cell publications who did not
publish new articles between 2008 and
2009. The dark gray, blue, and red nodesCell 1represent senior authors on papers that
used hESC lines only, hiPSC lines only,
or both types of lines, respectively. In
Figure 3, consider Harvard University’s
George Daley, who published 12 papers
on human pluripotent stem cells during
this time with 6 articles listing him as last
author. Daley is a rare senior author in
our database in that, during 2008–2009,
he published papers using hESCs alone,
hiPSCs alone, and both cell types. We
thus code him as a last author who has
used both hESCs and hiPSCs. Daley
appears in our network images as a large
red circle.
Finally, the relative position of nodes in
these images is meaningful. The network
drawings are optimized using a pair of
‘‘spring embedder’’ algorithms that use
the connectivity of a network system to
establish the Euclidean distance among
nodes (Fruchterman and Reingold, 1991;
Kamada and Kawai, 1989). A position in
the outer ring of the image represents45, June 10, 2011 ª2011 Elsevier Inc. 823
Figure 4. Network of Last Authors Using hiPSCs
This network image represents coauthorship connections among the 69 last authors working with hiPSCS in 2008–2009. The large network on the left side of the
figure includes 33 (47.83%) authors, dominated by researchers at Harvard University and the University of Wisconsin. The ‘‘star’’ in the center contains five last
authors connected to Shinya Yamanaka.a collaboration profile that has few ties
into the most connected portions of the
field. Likewise, scientists who are posi-
tioned close together are proximate
because they are direct collaborators or
they share coauthors in common,
creating relatively short indirect network
paths between them.
Figure 3 represents 90.8% of pluripo-
tent stem cell scientists. If hiPSCs are
a widely disseminated technology that
allow newcomers to enter the field without
recourse to prior working relationships
with established hESC investigators, we
would expect to see (1) more blue nodes
than red nodes, indicating that a large
portion of senior authors are using hiPSCs
instead of hESCs; (2) red and blue nodes
smaller than gray nodes, indicating that
those researchers using hiPSCs alone or
in concert with hESCs are newer, less
prolific investigators; and (3) red and
blue nodes nearer the periphery of the
image than its center, indicating that824 Cell 145, June 10, 2011 ª2011 Elsevier Insenior investigators using hiPSCs are
relatively less well connected to the
researchers at the established core of
the hESC network.
Examining Figure 3 suggests that none
of these expectations are born out. Red
nodes outnumber blue nodes, with 55
senior investigators publishing papers
using both hESCs and hiPSCs in 2008–
2009 compared to only 14 senior investi-
gators publishing papers using hiPSCs
alone. Many red nodes are large, repre-
senting prolific authors that use both cell
types. Blue nodes tend to be small, sug-
gesting that the last authors on papers
with only hiPSCs either are junior in the
larger pluripotent field or are senior inves-
tigators in allied stem cell disciplines and
are experimenting with reprogramming.
Finally, although red and blue nodes
appear spread across the entire network
image in Figure 3, the majority of senior
authors using hiPSCs are clustered in
a band of large red nodes that crossesc.the lower left quadrant of the figure. In
other words, many of the investigators
using hiPSCs are established, prolific
hESC scientists who are connected to
each other directly or through short indi-
rect paths defined by shared coauthors.
Such close indirect connections occur in
many fields as senior investigators hire
postdoctoral fellows trained in the labs
of other established investigators, or as
departing scientists carry past collabora-
tions with them to new faculty positions.
Figure 4 delves deeper into the rela-
tionships between senior authors using
hiPSC lines. To create Figure 4, we first
extracted all 69 red and blue nodes from
Figure 3 and then reoptimized the
connections so that the constellations of
coauthorship among senior authors
become clear. Figure 4 suggests that the
clustering of red nodes in Figure 3 results
largely from the large set of 33 (47.83%)
senior stem cell investigators connected
by past and current collaborations. This
cluster centers on researchers at Harvard
University and the University of Wiscon-
sin, and it contains some of the most
prominent scientists working with both
hiPSCs and hESCs. It also includes 5 of
the 14 (35.7%) senior investigators who
have published as last authors using
hiPSCs alone. In other words, the most
significant cluster of established hESC
researchers using hiPSCs is also the
source of more than 1/3 of the senior
authors who are deploying hiPSC lines
alone. Indeed, in Figure 4, the senior
authors using only hiPSCs (blue dia-
monds) appear evenly split between
those connected to and those uncon-
nected to senior authors who have used
hESCs and hiPSCs together (red circles).
Conclusions and Policy
Implications
Our analyses provide a mixed picture
of whether reprogramming technologies
have engaged new investigators to reor-
ient the stem cell field. It is clear that
iPSCs are not eclipsing hESCs but have
instead emerged as a complimentary
technology. Although the use of iPSCs is
increasing at a rate greater than that
observed for hESCs, we believe this is
due largely to lower regulatory thresholds,
less ethical worry, increased access, and
scientific excitement. In terms of who
uses specific cell lines, iPSCs may not
be lowering barriers to pluripotent stem
cell research. A large proportion of early
hiPSC adopters are established users of
hESCs, which suggests three main
conclusions. First, the technology may
be facile, but not so easy that a flood of
new investigators is entering the pluripo-
tent stem cell field. Experience with
hESCs appears to transfer to research
that employs induced pluripotent lines.
Second, the incentives to use both types
of cells in comparative studies are high.
Finally, the furious activity we observe
on the part of senior hESC researchers
may be motivated by scientific curiosity
and a dedication to pragmatic choices in
uncertain funding environments. Scien-
tists see themselves entering a new era
defined by pluripotency, and it is only
natural that experience in establishing
primary cultures and derivations gives
these labs an advantage no matter what
cell enters the scene. That reprogrammed
cells may unlock the mysteries of hu-man disease is important for these re-
searchers but comprise a different set of
objectives.
On August 23, 2010, aWashington D.C.
district judge, Royce Lamberth, issued
a preliminary injunction to block Barak
Obama’s 2009 executive order expanding
funding for hESC research. The plaintiffs,
including two adult stem cell researchers,
The Christian Medical Association, and
the Nightlight Christian Adoptions (an
embryo adoption agency), sued the NIH
because they believed that the NIH’s
Guidelines for Research Using Human
Pluripotent Stem Cells violated the
restrictions on human embryo research
under the Dickey-Wicker Amendment.
This amendment, which has been added
to the yearly Health and Human Services
(HHS) appropriations bill since 1996,
prohibits HHS from funding research
that destroys human embryos. During
that time, congress and three administra-
tions agreed that funds could be used for
research projects that did not destroy
embryos but studied the lines themselves.
In a stunning reversal of this longstanding
agreement, Lamberth held that federal
funding violates Dickey-Wicker. His
injunction stopped new federal funding
hESC research and threw more than
a decade of work on human pluripotent
stem cells into doubt.
A month later, a three-judge federal
appeals panel paused the injunction while
it considered an appeal by the Obama
administration. On April 29th, 2011 the
panel reversed Lamberth’s ruling,
concluding that ‘‘the plaintiffs are unlikely
to prevail because the Dickey-Wicker
Amendment is ambiguous and the NIH
seems reasonably to have concluded
that, although Dickey-Wicker bars fund-
ing for the destructive act of deriving an
[h]ESC from an embryo, it does not
prohibit funding a research project in
which an [h]ESC will be used’’ (Sherley v.
Sibelius, 2011). Lamberth now has two
motions for judgment in front of him, one
by the plaintiffs and one by the defen-
dants, the US government. He granted
the original injunction based on the likeli-
hood that the plaintiffs would prevail.
Three judges appointed by conservative
Republican presidents decided, 2 to 1,
to allow this research. However, Lam-
berth might maintain his original position,
or he could rule on one of the judgmentsCell 1and either allow federal funding for hESC
research or ban it outright.
The deeper implications of a federal ban
or restrictions on hESC research are
largely missing from the policy discus-
sions surrounding the Lamberth decision.
Restrictions, regulatory uncertainty, and
spurious court decisions have undoubt-
edly retarded progress in the pluripotent
stem cell field. We now have new data
pointing to ‘‘collateral damage’’ that could
be caused by ill conceived and politically
motivated policy prescriptions. According
to thedata presented here, an entirely new
technology, forged out of the crucible of
political controversy, is at risk. A major
finding from our study is that iPSCs and
hESCsare deeply intertwined and interde-
pendent technologies. We see a decade
of research using human embryonic cell
types carrying the new wave of reprog-
ramming technologies. And, although
hESC research has made great strides
over this time, our lack of understanding
of early human development cannot be
overestimated. Unraveling the properties
of the human embryo has broad conse-
quences for both regenerative medicine
and assisted reproductive technologies.
The growing and significant number of
comparative studies and experiments
using hESCs, combined with the heavy
use of iPSCs by senior hESC investiga-
tors, suggest that any federal policy that
would deny funding for embryonic stem
cell research would torpedo a nascent
and exciting discovery that is propelling
new directions in the biological sciences.
Indeed, just as political debate draws arti-
ficial boundaries between adult and
embryonic cell types, it is dangerous to
assume the same divisions can be made
for pluripotent cell types. The secrets of
cells have no boundaries.
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